GlassScriptPhysician profile
Jacques Mario Azzi
NPI 1184036964
$7,402.90
in general payments reported to CMS, 2019-2025
12 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.00 · 2021: $125 · 2022: $1,233 · 2023: $3,127 · 2024: $1,286 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,735 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,735.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,211.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $3,610.85 | 2022-2025 | |
| Kite Pharma, INC. | $1,019.92 | 2024-2025 | Yescarta |
| Adaptive Biotechnologies Corporation | $1,000.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $734.47 | 2023-2025 | |
| Sobi, INC | $202.50 | 2025 | |
| Merck Sharp & Dohme LLC | $174.69 | 2023-2025 | Prevymis, Zerbaxa, Dificid |
| Seagen INC. | $132.74 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $128.87 | 2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Abbvie INC. | $118.06 | 2023 | Epkinly |
| Amgen INC. | $99.00 | 2020 | |
| Celgene Corporation | $56.80 | 2024-2025 | Breyanzi, Abecma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacques Azzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.